Aditxt, Inc. ( (ADTX) ) just unveiled an update.
On April 18, 2025, Aditxt, Inc. announced that its subsidiary, Pearsanta, Inc., received IRB approval to initiate clinical studies for a blood-based diagnostic test for endometriosis. This development marks a significant step towards providing a non-invasive solution for early detection of endometriosis, a condition affecting 10 to 20% of women of childbearing age. The test utilizes Mitomic technology to identify disruptions in mitochondrial DNA, aiming to offer a timely and precise diagnostic option that could potentially reduce the need for invasive procedures like laparoscopic surgery.
More about Aditxt, Inc.
Aditxt, Inc. operates in the biotechnology industry, focusing on developing innovative diagnostic solutions. Its subsidiary, Pearsanta, Inc., specializes in early disease detection, with a particular emphasis on non-invasive diagnostic tests.
YTD Price Performance: -95.30%
Average Trading Volume: 3,091,853
Technical Sentiment Signal: Strong Buy
Current Market Cap: $252.8M
Learn more about ADTX stock on TipRanks’ Stock Analysis page.